

Vasomedical, Inc.

Corporate Fact Sheet

Profile: Vasomedical, Inc. (OTC BB: VASO.OB) is the market leader in EECP® external counterpulsation therapy and services for the treatment of cardiovascular diseases. EECP® therapy serves to increase circulation in areas of the heart with less than adequate blood supply and improve systemic vascular function. The system's action, which pulses counter to the heart's beating, increases blood flow to the heart muscle and decreases the heart's workload, creating a greater oxygen supply for the heart muscle while lowering the heart's need for oxygen.

FDA-cleared EECP® treatment is currently indicated for use in the treatment of angina, congestive heart failure (CHF), cardiogenic shock, and acute myocardial infarction. EECP® therapy has been shown to be an effective treatment option for patients with difficult to treat heart diseases where medical therapies and invasive procedures such as angioplasty do not provide adequate relief.

Market

Overview: More than five million people in the United States suffer from CHF and approximately 6.8 million people suffer from angina. With more than 550,000 heart failure and 400,000 angina cases diagnosed annually, it is a rapidly growing problem. Despite advances in medical therapy over the past decade many patients fail to improve with treatment or experience rapid recurrence of symptoms. EECP® therapy provides these patients with a new non-invasive treatment option. More than 800 physicians use EECP® therapy to treat approximately 19,000 angina and heart failure patients annually.

Ownership: OTC BB: VASO.OB; Founded in 1987

Management:	John C. K. Hui, Ph.D.	President & Chief Executive Officer, Director
	Tricia Efstathiou, CPA	Chief Financial Officer, Director
	Harold Kaefer	Vice President, Engineering and Manufacturing
	Larry Liebman	Vice President, Sales

Employees: 20

Contact 800-455-3327 ext 790

Information: investorrelations@vasomedical.com